PHARMENA
Research PHARMENA (PHR.WA) on Bullrun: market cap PLN 36.31M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPHR.WA
- ExchangeXWAR
- CountryPoland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyPLN
- Market capPLN 36.31M
- Financial periodQ2 2026
- RevenuePLN 242.00K
- Net income-PLN 996.00K
- Free cash flow-PLN 6.37M
- Gross margin81.0%
Valuation Snapshot
latest market cap is PLN 36.31M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-06 | PLN 36.31M | n/a | 75.2% | 2.36 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 2.36 PLN.
About PHARMENA
Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. The company also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, it is involved in research and development of therapeutic applications of 1 MNA as an anti-inflammatory and anti-fibrotic drug;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PHARMENA's market cap?
PHARMENA's market capitalization is PLN 36.31M.
What does PHARMENA do?
Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. The company also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, it is involved in research and development of therapeutic applications of 1 MNA as an anti-inflammatory and anti-fibrotic drug; and research and development at pulmonary fibrosis, respiratory tract infections, including viral infections, COVID-19, inflammatory diseases, metabolic diseases and other therapeutic applications. The company was incorporated in 2002 and is based in Lódz, Poland.